— Know what they know.
Not Investment Advice

APUS AMEX

Apimeds Pharmaceuticals US, Inc
1W: -55.6% 1M: +22.4% 3M: -62.6% YTD: -80.7% 1Y: -81.2%
$3.22
-0.88 (-21.46%)
 
Weekly Expected Move ±68.6%
$-1 $1 $3 $5 $8
AMEX · Healthcare · Biotechnology · Tech Score Neutral · Power 48 · $4.9M mcap · 563192 float · 267.23% daily turnover · Short 44% of daily vol

Cash Flow Trends

Operating Cash Flow
-$734K -16.8% ▼
Capital Expenditures
$0 +0.0% ▲
Free Cash Flow
-$734K -16.8% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$407K -200.7% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024
— Operating Activities —
Net Income-$1M-$669K-$778K-$1M
Depreciation & Amort.$0$0$0$0
Stock-Based Comp.$194K$194K$70K$0
Change in Working Capital$3K-$2K$42K$539K
Other Non-Cash Items$7K$29K$38K$118K
Operating Cash Flow-$823K-$448K-$628K-$734K
— Investing Activities —
Capital Expenditures$0$0$0$0
Acquisitions (Net)$0$0$0$0
Investment Purchases$0$0$0$0
Investment Sales$0$0$0$0
Other Investing$0$0$0$0
Investing Cash Flow$0$0$0$0
— Financing Activities —
Net Debt Issuance$400K$260K$0$250K
Stock Repurchased$0$0$0$0
Dividends Paid$0$0$0$0
Other Financing$0$23K-$23K$76K
Financing Cash Flow$400K$283K$1M$326K
Net Change in Cash-$423K-$165K$404K-$407K
Cash End of Period$171K$6K$410K$3K
Free Cash Flow-$823K-$448K-$628K-$734K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms